Craft
  • Home
  •  / Genocea Biosciences
Genocea Biosciences

Genocea Biosciences

Revenue

$1.6 M

FY, 2021

Market Capitalization

$758.3 K

2022-09-21

Genocea Biosciences Summary

Company summary

Overview
Genocea Biosciences is a biopharmaceutical company developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company is using its proprietary ATLAS antigen identification platform to build a pipeline of immunotherapies that currently includes its lead candidate, GEN-003, an immunotherapy for genital herpes, and GEN-009, its first neoantigen cancer vaccine.
Type
Public
Founded
2006
HQ
Cambridge, MA, US | view all locations
Website
https://www.genocea.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Girish Aakalu

    Girish Aakalu, Chief Business Officer

    • Chip Clark

      Chip Clark, President and Chief Executive Officer

      • Diantha Duvall

        Diantha Duvall, Chief Financial Officer

        • Jessica Baker Flechtner, Chief Scientific Officer

          LocationsView all

          1 location detected

          • Cambridge, MA HQ

            United States

            100 Acorn Park Dr

          Genocea Biosciences Financials

          Summary financials

          Revenue (Q1, 2022)
          $270.0K
          Net income (Q1, 2022)
          ($16.0M)
          Cash (Q1, 2022)
          $20.1M

          Footer menu